Treatment with relacorilant plus standard chemotherapy was shown in a clinical trial to significantly improve survival compared with chemo alone for people with hard-to-treat ovarian…
Gynecological cancer
The U.S. Food and Drug Administration (FDA) has granted its breakthrough therapy designation to sofetabart mipitecan as a potential treatment for people with platinum-resistant epithelial…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to ETX-19477, an oral treatment for ovarian cancer currently in early clinical testing.
Ernexa Therapeutics is making headway on plans to start clinical testing of ERNA-101, its stem cell therapy designed to treat ovarian cancer. The U.S.
A Phase 1 clinical trial testing the experimental therapy IDE034 in people with various types of cancer, including gynecological cancers, is expected to start…
Dosing has begun in a Phase 3 clinical trial testing Enhertu (trastuzumab deruxtecan) as a maintenance treatment for certain people with ovarian cancer. The…
A new experimental therapy, DT2216, has begun testing in a clinical trial for people with hard-to-treat ovarian cancer, a significant step forward announced by…
The Ovarian Cancer Research Alliance (OCRA) launched a project to push lawmakers to enact legislation that will improve the lives of people affected by…
A committee of the World Health Organization (WHO) has approved an international nonproprietary name (INN) for Anixa Biosciences’ experimental cell therapy for ovarian cancer. The…
A combination of chemotherapy and immune-modulating therapies administered directly into the abdomen may help control ovarian cancer that has spread within the abdominal cavity, data…
